Coronary embolization following electrical cardioversion in a patient treated with dabigatran

Gagliardi, Laura; Guerbaaï, Raphaëlle-Ashley; Marlière, Stéphanie; Bouvaist, Hélène; Ennezat, Pierre‐Vladimir

doi:10.1016/j.ijcard.2014.05.030

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…44 Two other patients who suffered embolic sequelae received dabigatran in the presence of significant valvular disease 45 or off-label dosing (110 mg). 46 These case reports further emphasize careful consideration of medical history and dosing pericardioversion use; however, they do not provide sufficient evidence to discourage dabigatran use pericardioversion.…”

Section: Discussionmentioning

confidence: 94%

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence

2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence

2017

View full text Add to dashboard Cite

show abstract

“…Схожая природа тромбоза дает основания полагать, что новые пероральные антикоагулянты также будут эффективны для лечения эмболического ИМ. Применение антикоагулянтов при эмболическом ИМ у пациентов с ФП широко не изучалось, и доступные данные ограничиваются описаниями клинических случаев [21][22][23][24][25]. В большинстве случаев для дальнейшего лечения пациентов использовался варфарин, однако существует опыт назначения апиксабана [25].…”

Section: лечение пациентов с эмболией коронарных артерийunclassified

Embolic Myocardial Infarction. Experience in Diagnosis and Management

Shilova¹,

Gilyarova²,

Андреев³

et al. 2018

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) is one of the main causes of morbidity and mortality, both in the Russian Federation and around the world. Approximately, in up to 10% of patients with clinical diagnostic features of AMI, early angiography does not reveal an occluded vessel or possibly any evidence of coronary artery disease. These patients constitute an intriguing subgroup referred to as “Myocardial Infarction with Non-Obstructive Coronary Arteries” (MINOCA). MINOCA is a collective concept that unites many different pathologies, which determines the essential heterogeneity of the etiological factors. Coronary artery embolism is recognized as an important non-atherosclerotic cause of AMI. In turn, the most common underlying disease in those with coronary embolism is the atrial fibrillation. The advantages of reperfusion strategy and cardioprotective therapy in the treatment of obstructive arteriosclerosis are well studied, widely presented in the literature and supported by a strong evidence base, while the issues of diagnosis and treatment of patients with MINOCA are currently widely discussed We present two clinical cases of embolic myocardial infarction in patients with atrial fibrillation, diagnosed in our clinic in 2017.

show abstract